EyePoint Pharmaceuticals Inc (EYPT): www.asx.com.au/asxpdf/20131001/pdf/42jr3...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	4
Posts	123
Boards Moderated	0
Alias Born	12/13/2008

jupp

Re: None

Tuesday, 10/01/2013 2:54:10 AM

Tuesday, October 01, 2013 2:54:10 AM

www.asx.com.au/asxpdf/20131001/pdf/42jr3ndrbcd0v7.pdf

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care Excellence (NICE) issued final draft guidance recommending ILUVIEN as an option for the treatment of chronic diabetic macular edema (DME) that is insufficiently responsive to available therapies in pseudophakic eyes (those that have already undergone cataract surgery). This recommendation reverses the final draft guidance previously issued by NICE with respect to this subgroup of chronic DME patients.

NICE's final guidance recommending ILUVIEN to the National Health Service (NHS) is expected to be published in November 2013, which would result in NHS reimbursement in England and Wales under the patient access scheme submitted by Alimera Sciences, pSivida's licensee.